RenoVate Therapeutics

🗓 Founded 2022👥 5 employees
Biotechnology Research
LinkedIn
RenoVate Therapeutics is an early-stage biotechnology company based on the research conducted by Prof. Benjamin Dekel, Head of the Pediatric Stem cell Research Institute and the Director of the Division of Pediatric Nephrology at Sheba Medical Center, Israel. RenoVate is developing regenerative biomolecules aimed to repair and rejuvenate kidneys. The regenerative biomolecules are derived from cells expanded from a patient's own urine using proprietary technology. This groundbreaking IP will ultimately prevent the need for dialysis and kidney transplantations.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was RenoVate Therapeutics founded?
RenoVate Therapeutics was founded in 2022.
What industry is RenoVate Therapeutics in?
RenoVate Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.